New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules Proceedings of a conference held on April 15–16, 1996, in New Orleans, USA, ... educational grant from Boehringer Ingelheim - Image 1

£76.42

Springer New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules Proceedings of a conference held on April 15–16, 1996, in New Orleans, USA, ... educational grant from Boehringer Ingelheim

Name: New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules Proceedings of a conference held on April 15-16, 1996, in New Orleans, USA, ... educational grant from Boehringer Ingelheim
Brand: Springer
Price: 76.42 GBP
Availability: InStock

Pharmacology

This is the most expensive it has ever been. Walk away.

£76 today · previous high £76 · all-time low £76

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 62 days · 62 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 62 days • 1 price levels

Days at Price

Price Analysis

Most common price: £76 (62 days, 100.0%)

Price range: £76 - £76

Price levels: 1 different prices over 62 days

Description

For the past 100 years the mainstay of therapy for rheumatoid arthritis (RA) has been aspirin or other drugs of the non-steroid anti-inflammatory group. In 1971 Vane pro posed that both the beneficial and toxic actions of these drugs was through inhibition of prostaglandin synthesis. The recent discovery that prostaglandins responsible for pain and other symptoms at inflammatory foci are synthesized by an inducible cyclooxygenase (COX-2) that is encoded by a gene distinct from that of the consti tutive enzyme (COX-I) provided a new target for therapy of RA. A drug that would selectively inhibit COX-2 would hopefully produce the symptomatic benefit provided by existing NSAIDs without the gastrointestinal and renal toxicity due to the inhibition of COX-I. Drugs selective for COX-2 are now available. Experimental studies have shown them to be effective with minimal toxicity, and in clinical trials gastric and renal toxicities are less. Highly selective COX-2 inhibitors, perhaps designed with knowledge of the crystal structures of COX-I and COX-2, are also available. Other experimental studies, including those in animals lacking effective genes for COX-lor COX-2 and in experimental carcinomas, suggest there is still much to be learned of the pathophysiological functions of these enzymes. The inflammatory response is a complex reaction involving many mediators that derive from white blood cells, endothelial cells and other tissues. Preliminary data have revealed that inhibitors of the cytokines and adhesion molecules that play a crucial role in the migration of white cells to inflammatory sites may be useful in RA. About the Author Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids.

Product Specifications

Brand: Springer
Format: paperback
ASIN: 940106265X
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Other Branches of Medicine > Pharmacology
Domain: Amazon UK
Publication Date: 16 October 2012
Listed Since: 03 March 2013

Barcode

No barcode data available

Springer New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules Proceedings of a conference held on April 15–16, 1996, in New Orleans, USA, ... educational grant from Boehringer Ingelheim

This is the most expensive it has ever been. Walk away.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential

COX-2 Blockade in Cancer Prevention and Therapy (Cancer Drug Discovery and Development)

COX-2 Inhibitors (Milestones in Drug Therapy)

Side Effects of Anti-Inflammatory Drugs IV: The Proceedings of the IVth International Meeting on Side Effects of Anti-inflammatory Drugs, held in Sheffield, UK, 7–9 August 1995

Rheumatoid Arthritis: Recent Research Advances

Prostaglandins and Immunity: 4 (Prostaglandins, Leukotrienes, and Cancer, 4)

Metalloproteinases as Targets for Anti-Inflammatory Drugs (Progress in Inflammation Research)

Proteases and Their Receptors in Inflammation (Progress in Inflammation Research)

Eicosanoid Protocols: 120 (Methods in Molecular Biology, 120)

Arthritis Research: Volume 2: Methods and Protocols: 136 (Methods in Molecular Medicine, 136)

Cytokines and Joint Injury (Progress in Inflammation Research)

T Cells in Arthritis (Progress in Inflammation Research)

The Many Faces of Osteoarthritis

Prostaglandins, Leukotrienes, Lipoxins, and PAF: Mechanism of Action, Molecular Biology, and Clinical Applications (Gwumc Department of Biochemistry and Molecular Biology Annual Spring Symposia)

Polymyalgia Rheumatica and Giant Cell Arteritis

Arthritis and Related Affections: Clinic, Pathology, and Treatment

New Cytokines as Potential Drugs (Progress in Inflammation Research)

Rheumatoid Arthritis: Risk Factors, Health Effects and Treatment Options (Rheumatism and Musculoskeletal Disorders)

Leukocyte Recruitment, Endothelial Cell Adhesion Molecules, and Transcriptional Control: Insights for Drug Discovery

Leukocyte Recruitment, Endothelial Cell Adhesion Molecules, and Transcriptional Control: Insights for Drug Discovery

Arthritis Research: Volume 1: Methods and Protocols: 135 (Methods in Molecular Medicine, 135)

Drug Development: Molecular Targets for GI Diseases

Advances in Prostaglandin, Leukotriene, and other Bioactive Lipid Research: Basic Science and Clinical Applications: 525 (Advances in Experimental Medicine and Biology, 525)

Rheumatoid Arthritis: Methods and Protocols: 1868 (Methods in Molecular Biology, 1868)